Find Clinical Trials

182 Results

Protocol Code7	Study Title	Active Substance	Study Phase	Therapeutic Area
CL2-16257-096	Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid)…	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-16257-095	Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise…	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-16257-090	Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy…	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-16257-088	Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac…	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-16257-073	Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d.…	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-16257-062	Evaluation of the effects of 3 successive oral dosages (2.5; 5; 7.5 mg b.i.d.) of…	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-16257-060	Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg…	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-16257-053	Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure	IVABRADINES016257	Phase 2	Cardiovascular Diseases
CL2-12911-039	A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of…	STRONTIUM RANELATE	Phase 2	Rheumatology
CL2-09490-157	Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day…	PERINDOPRIL TERT BUTYLAMINE	Phase 2	Cardiovascular Diseases
CL2-066913-002	A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in…	S066913	Phase 2	Cardiovascular Diseases
CL2-05985-005	Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination…	AMLODIPINEPERINDOPRIL ARGININE	Phase 2	Cardiovascular Diseases
CL2-05720-005	Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin…	GLICLAZIDEMETFORMINES005720	Phase 2	Metabolism
CL2-05682-102	Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in…	MICRONISED PURIFIED FLAVONOID FRACTION	Phase 2	Cardiovascular Diseases
CL2-05682-099	Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease	MICRONISED PURIFIED FLAVONOID FRACTION	Phase 2	Cardiovascular Diseases
CL1-95005-001	Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer	TIPIRACILTRIFLURIDINE	Phase 1	Cancers
CL1-81694-001	Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid…	S081694	Phase 1	Cancers
CL1-80881-007	An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy,…	LUCITANIB	Phase 1-2	Cancers
CL1-78454-009	Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454…	ABEXINOSTATS078454	Phase 1	Cancers
CL1-78454-008	Phase I dose-escalation study of oral administration of the Histone Deacetylase (HDAC) Inhibitor S 78454…	ABEXINOSTATS078454	Phase 1	Cancers
CL1-78454-006	Phase I dose-escalation study of S 78454 (HDACi) p.o. in combination with FOLFOX in patients…	ABEXINOSTATS078454	Phase 1	Cancers
CL1-78454-005	Phase I dose-escalation study of oral administration of S 78454 given with a fixed dose…	ABEXINOSTATS078454	Phase 1	Cancers
CL1-78454-002	Phase I dose-escalation study of oral administration of Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in…	ABEXINOSTATS078454	Phase 1	Cancers
CL1-68587-003	A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have…	S068587UCART19	Phase 1	Cancers
CL1-68587-002	Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity…	S068587UCART19	Phase 1	Cancers